Developer docs
API playgroundTry for free, no card

Search company profiles

AcelRx Pharmaceuticals, Inc.

Full company profile

uuid00rj78s

Namestring
AcelRx Pharmaceuticals, Inc.
Legal namestring
Talphera
Websiteurl
acelrx.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Talphera (formerly AcelRx Pharmaceuticals, Inc.) is a San Mateo, California-based specialty pharmaceutical company developing drug-device products for medically supervised settings such as intensive care units, dialysis units, and operating rooms. The company's pipeline is built around the broad-spectrum serine protease inhibitor nafamostat mesylate. Its lead candidate, Niyad, is a lyophilized nafamostat formulation designed as a regional anticoagulant for the extracorporeal circuit during continuous renal replacement therapy (CRRT) and intermittent hemodialysis in patients who cannot tolerate heparin; it is regulated by FDA as a device, has received breakthrough device designation, and has a PMA submission filed with top-line data expected by end of 2025. A second nafamostat candidate, LTX-608, is being developed as a pharmaceutical (NDA submitted) for COVID-19, disseminated intravascular coagulation, acute respiratory distress syndrome, and acute pancreatitis.

The company's product portfolio also includes two 10 mL ready-to-use prefilled syringe candidates, Fedsyra (ephedrine hydrochloride) and PFS-02 (phenylephrine hydrochloride), developed in partnership with France-based Laboratoire Aguettant for perioperative and acute care hypotension. Following the 2023 divestiture of its legacy approved asset, the sublingual sufentanil product DSUVIA, to Alora Pharmaceuticals, Talphera's current revenue is limited to a 15% royalty on Alora's commercial net sales of DSUVIA, a 75% royalty on sales to the U.S. Department of Defense, and up to $116.5 million in contingent sales-based milestones. Future revenue depends on FDA approval and commercial launches of Niyad, LTX-608, Fedsyra, and PFS-02, with a planned enterprise field sales motion targeting hospitals and healthcare providers in medically supervised environments. Talphera is led by CEO Vincent J. Angotti with a board chaired by Adrian Adams and engages in ongoing virtual investor and analyst communications through a dedicated IR portal.

Short descriptiontext

Talphera (formerly AcelRx Pharmaceuticals) develops drug-device therapies for medically supervised settings, with lead candidate Niyad (nafamostat mesylate) as a regional anticoagulant for renal replacement therapy, plus pipeline assets in perioperative prefilled syringes and inflammatory indications.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersSan Mateo, United States
HQ citystring
San Mateo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, drug-device combinations, regional anticoagulants, prefilled syringes, renal replacement therapy
Industry4 codes
PRIMARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAKAK
Renal Care Ancillaries (Anemia Management Devices, Phosphate Binder Support, Nutrition Monitoring)
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1DSUVIA Royalty Revenue
TypeLicensing Royalties
Description

Following divestment of DSUVIA to Alora Pharmaceuticals in April 2023, Talphera receives a 15% royalty on commercial net sales, a 75% royalty on net sales to the US Department of Defense, and up to $116.5 million in sales-based milestone payments.

talphera.com
2Niyad (future commercial revenue)
TypeOne Time License
Description

Upon FDA approval, Niyad will be commercialized as the first FDA-approved regional anticoagulant for extracorporeal circuits, targeting patients undergoing renal replacement therapy who cannot tolerate heparin.

talphera.com
3Prefilled Syringes (future commercial revenue)
TypeOne Time License
Description

Fedsyra and PFS-02 prefilled syringes will be commercialized pending regulatory approvals, in partnership with Laboratoire Aguettant.

talphera.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1DSUVIA
Description

FDA-approved acute pain product, divested to Alora Pharmaceuticals in April 2023. Talphera retains 15% royalty on commercial net sales, 75% royalty on DoD net sales, and up to $116.5M in sales-based milestone payments.

talphera.com
+4 more records
Core offering1 text field

Talphera (formerly AcelRx Pharmaceuticals) develops and commercializes innovative therapies and drug-device products for use in medically supervised care settings. Its lead product candidate Niyad® (nafamostat mesylate) is a regional anticoagulant for extracorporeal circuits during continuous renal replacement therapy (CRRT), regulated as a device by the FDA. The company also develops prefilled syringe candidates Fedsyra™ (ephedrine) and PFS-02 (phenylephrine) for perioperative hypotension, and LTX-608™, a nafamostat formulation for inflammatory and antiviral indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Nafamostat demonstrated significant safety and efficacy improvements over current standards of care according to 2022 meta-analysis.
Product overview1 text field

Talphera (formerly AcelRx Pharmaceuticals) is a pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. The company's product portfolio consists of pipeline candidates and a divested approved product. Lead candidate Niyad® (nafamostat mesylate) is a regional anticoagulant for renal replacement therapy (RRT) regulated as a device. Additional pipeline candidates include LTX-608™ (nafamostat for various inflammatory/anti-viral indications regulated as pharmaceuticals), and two pre-filled syringe candidates Fedsyra™ (ephedrine) and PFS-02 (phenylephrine) developed in partnership with Laboratoire Aguettant. The company previously had DSUVIA, an FDA-approved acute pain product, which was divested to Alora Pharmaceuticals in 2023. The company continues to receive royalty payments from DSUVIA sales.

Product and service5 records
1Niyad®
CategoryDrug-device product (regional anticoagulant)
Description

Niyad® (nafamostat mesylate) is a lyophilized regional anticoagulant product candidate for injection into the extracorporeal circuit during renal replacement therapy (RRT). It is regulated as a device by the FDA and is positioned to be the first FDA-approved regional anticoagulant for use in the extracorporeal circuit, with an 8-minute half-life enabling rapid clearance from blood.

2LTX-608™
CategoryPharmaceutical (nafamostat formulation)
Description

LTX-608 is a nafamostat product candidate regulated as a pharmaceutical for various indications including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. It has broad anti-inflammatory and antiviral potential.

3Fedsyra™
CategoryPrefilled syringe pharmaceutical
Description

Fedsyra is a 10 mL ready-to-use prefilled syringe of ephedrine hydrochloride in development for the treatment of hypotension during general anesthesia. Developed in partnership with Laboratoire Aguettant to streamline care with waste reduction, time savings, improved safety, and lower medication error risk.

4PFS-02
CategoryPrefilled syringe pharmaceutical
Description

PFS-02 is a 10 mL ready-to-use prefilled syringe of phenylephrine hydrochloride in development for the treatment of hypotension due to vasodilation, as well as for acute pancreatitis and clotting diseases. Developed in partnership with Laboratoire Aguettant.

5DSUVIA
CategoryAcute pain pharmaceutical (divested, royalty-bearing)
Description

DSUVIA was an FDA-approved sublingual sufentanil tablet for acute pain management in medically supervised settings. It was divested to Alora Pharmaceuticals in April 2023, with Talphera retaining a 15% royalty on commercial net sales, 75% royalty on DoD net sales, and up to $116.5 million in sales-based milestone payments.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Talphera partnered with the France-based pharmaceutical company Laboratoire Aguettant to develop prefilled syringe product candidates Fedsyra (ephedrine) and PFS-02 (phenylephrine). The partnership leverages Aguettant's expertise in pharmaceutical manufacturing to create ready-to-use injectable medications for perioperative and acute-care settings.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Baxter is a global medical products company with significant CRRT/dialysis solutions (e.g., PrisMax, HDx therapy) and a broad injectable pharma portfolio, overlapping directly with Talphera's Niyad (CRRT anticoagulation) and prefilled syringe strategies.

TypeBroad incumbent
Description

Fresenius is the largest dialysis products and services provider globally, manufacturing CRRT machines and dialyzers. It is the most natural incumbent peer for Niyad given its dominant share of the U.S. dialysis patient population that would be treated with Niyad.

TypeDirect peer
Description

B. Braun is a leading manufacturer of prefilled syringes (e.g., ephedrine, phenylephrine ready-to-use injectables) and renal care products, directly comparable to Talphera's Fedsyra/PFS-02 portfolio and the renal care positioning of Niyad.

TypeBroad incumbent
Description

Hikma is a multinational specialty pharmaceutical company with a strong hospital injectables business, including prefilled syringes. It is comparable to Talphera in targeting the same perioperative and acute care hospital channel with injectable presentations.

TypeDirect peer
Description

ICU Medical specializes in IV infusion therapy, critical care, and dialysis connection/disposables, making it a direct peer in the hospital-based infusion and renal care channels that Talphera's products are designed to serve.

TypeEmerging player
Description

Outset Medical produces the Tablo hemodialysis system used in hospitals and at home. As a CRRT/IHD-adjacent company, it shares the renal replacement therapy customer base that Niyad would address.

TypeEmerging player
Description

Amphastar is a specialty injectable pharmaceutical company that develops and markets injectable generic and proprietary products, including hospital-based injectables. It is comparable to Talphera's injectable pharmaceutical pipeline and the prefilled syringe strategy.

TypeEmerging player
Description

ANI Pharmaceuticals is a specialty generics and branded pharmaceutical company with a portfolio in critical care and hospital injectables, with a comparable small-cap specialty pharma profile to Talphera.

TypeBroad incumbent
Description

BD is a global leader in prefilled syringes, injection systems, and drug delivery devices, competing with Talphera's Fedsyra and PFS-02 prefilled syringe products in the perioperative and acute care hospital channel.

TypeEmerging player
Description

Eagle Pharmaceuticals is a specialty pharma focused on hospital-based injectables and ready-to-use formulations, with overlapping strategy around ready-to-use syringe presentations in critical care settings similar to Fedsyra and PFS-02.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AcelRx Pharmaceuticals, Inc.

Specialty Pharmaceuticalsacelrx.com

Talphera (formerly AcelRx Pharmaceuticals) develops drug-device therapies for medically supervised settings, with lead candidate Niyad (nafamostat mesylate) as a regional anticoagulant for renal replacement therapy, plus pipeline assets in perioperative prefilled syringes and inflammatory indications.

What AcelRx Pharmaceuticals, Inc. does

Talphera (formerly AcelRx Pharmaceuticals, Inc.) is a San Mateo, California-based specialty pharmaceutical company developing drug-device products for medically supervised settings such as intensive care units, dialysis units, and operating rooms. The company's pipeline is built around the broad-spectrum serine protease inhibitor nafamostat mesylate. Its lead candidate, Niyad, is a lyophilized nafamostat formulation designed as a regional anticoagulant for the extracorporeal circuit during continuous renal replacement therapy (CRRT) and intermittent hemodialysis in patients who cannot tolerate heparin; it is regulated by FDA as a device, has received breakthrough device designation, and has a PMA submission filed with top-line data expected by end of 2025. A second nafamostat candidate, LTX-608, is being developed as a pharmaceutical (NDA submitted) for COVID-19, disseminated intravascular coagulation, acute respiratory distress syndrome, and acute pancreatitis.

The company's product portfolio also includes two 10 mL ready-to-use prefilled syringe candidates, Fedsyra (ephedrine hydrochloride) and PFS-02 (phenylephrine hydrochloride), developed in partnership with France-based Laboratoire Aguettant for perioperative and acute care hypotension. Following the 2023 divestiture of its legacy approved asset, the sublingual sufentanil product DSUVIA, to Alora Pharmaceuticals, Talphera's current revenue is limited to a 15% royalty on Alora's commercial net sales of DSUVIA, a 75% royalty on sales to the U.S. Department of Defense, and up to $116.5 million in contingent sales-based milestones. Future revenue depends on FDA approval and commercial launches of Niyad, LTX-608, Fedsyra, and PFS-02, with a planned enterprise field sales motion targeting hospitals and healthcare providers in medically supervised environments. Talphera is led by CEO Vincent J. Angotti with a board chaired by Adrian Adams and engages in ongoing virtual investor and analyst communications through a dedicated IR portal.

AcelRx Pharmaceuticals, Inc. firmographics

Firmographics
Name
AcelRx Pharmaceuticals, Inc.
Legal name
Talphera
Website
https://acelrx.com
Company type
Private
Operating status
Operating
Short description
Talphera (formerly AcelRx Pharmaceuticals) develops drug-device therapies for medically supervised settings, with lead candidate Niyad (nafamostat mesylate) as a regional anticoagulant for renal replacement therapy, plus pipeline assets in perioperative prefilled syringes and inflammatory indications.
Ownership category
akta.pro rank

AcelRx Pharmaceuticals, Inc. industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAKAK
Renal Care Ancillaries (Anemia Management Devices, Phosphate Binder Support, Nutrition Monitoring)
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Drug-device combinations
  • Regional anticoagulants
  • Prefilled syringes
  • Renal replacement therapy

Where AcelRx Pharmaceuticals, Inc. is headquartered

Location

Headquarters

HQ city
San Mateo
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AcelRx Pharmaceuticals, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Revenue model

  1. DSUVIA Royalty Revenue: Following divestment of DSUVIA to Alora Pharmaceuticals in April 2023, Talphera receives a 15% royalty on commercial net sales, a 75% royalty on net sales to the US Department of Defense, and up to $116.5 million in sales-based milestone payments.
  2. Niyad (future commercial revenue): Upon FDA approval, Niyad will be commercialized as the first FDA-approved regional anticoagulant for extracorporeal circuits, targeting patients undergoing renal replacement therapy who cannot tolerate heparin.
  3. Prefilled Syringes (future commercial revenue): Fedsyra and PFS-02 prefilled syringes will be commercialized pending regulatory approvals, in partnership with Laboratoire Aguettant.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

AcelRx Pharmaceuticals, Inc. product offering

Product offering

Core offering

Talphera (formerly AcelRx Pharmaceuticals) develops and commercializes innovative therapies and drug-device products for use in medically supervised care settings. Its lead product candidate Niyad® (nafamostat mesylate) is a regional anticoagulant for extracorporeal circuits during continuous renal replacement therapy (CRRT), regulated as a device by the FDA. The company also develops prefilled syringe candidates Fedsyra™ (ephedrine) and PFS-02 (phenylephrine) for perioperative hypotension, and LTX-608™, a nafamostat formulation for inflammatory and antiviral indications.

Product overview

Talphera (formerly AcelRx Pharmaceuticals) is a pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. The company's product portfolio consists of pipeline candidates and a divested approved product. Lead candidate Niyad® (nafamostat mesylate) is a regional anticoagulant for renal replacement therapy (RRT) regulated as a device. Additional pipeline candidates include LTX-608™ (nafamostat for various inflammatory/anti-viral indications regulated as pharmaceuticals), and two pre-filled syringe candidates Fedsyra™ (ephedrine) and PFS-02 (phenylephrine) developed in partnership with Laboratoire Aguettant. The company previously had DSUVIA, an FDA-approved acute pain product, which was divested to Alora Pharmaceuticals in 2023. The company continues to receive royalty payments from DSUVIA sales.

Differentiator

Problem solved

Functional benefit

Brands

  • DSUVIA: FDA-approved acute pain product, divested to Alora Pharmaceuticals in April 2023. Talphera retains 15% royalty on commercial net sales, 75% royalty on DoD net sales, and up to $116.5M in sales-based milestone payments.
  • Niyad
  • LTX-608
  • Fedsyra
  • PFS-02

Products and services

  • Niyad® Niyad® (nafamostat mesylate) is a lyophilized regional anticoagulant product candidate for injection into the extracorporeal circuit during renal replacement therapy (RRT). It is regulated as a device by the FDA and is positioned to be the first FDA-approved regional anticoagulant for use in the extracorporeal circuit, with an 8-minute half-life enabling rapid clearance from blood.
  • LTX-608™ LTX-608 is a nafamostat product candidate regulated as a pharmaceutical for various indications including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. It has broad anti-inflammatory and antiviral potential.
  • Fedsyra™ Fedsyra is a 10 mL ready-to-use prefilled syringe of ephedrine hydrochloride in development for the treatment of hypotension during general anesthesia. Developed in partnership with Laboratoire Aguettant to streamline care with waste reduction, time savings, improved safety, and lower medication error risk.
  • PFS-02 PFS-02 is a 10 mL ready-to-use prefilled syringe of phenylephrine hydrochloride in development for the treatment of hypotension due to vasodilation, as well as for acute pancreatitis and clotting diseases. Developed in partnership with Laboratoire Aguettant.
  • DSUVIA DSUVIA was an FDA-approved sublingual sufentanil tablet for acute pain management in medically supervised settings. It was divested to Alora Pharmaceuticals in April 2023, with Talphera retaining a 15% royalty on commercial net sales, 75% royalty on DoD net sales, and up to $116.5 million in sales-based milestone payments.

Quantifiable outcome

  • Nafamostat demonstrated significant safety and efficacy improvements over current standards of care according to 2022 meta-analysis.

Companies that use AcelRx Pharmaceuticals, Inc.

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

AcelRx Pharmaceuticals, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

AcelRx Pharmaceuticals, Inc. partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Laboratoire AguettantcoreStrategic or Co-development Partner · 1 January 2023Talphera partnered with the France-based pharmaceutical company Laboratoire Aguettant to develop prefilled syringe product candidates Fedsyra (ephedrine) and PFS-02 (phenylephrine). The partnership leverages Aguettant's expertise in pharmaceutical manufacturing to create ready-to-use injectable medications for perioperative and acute-care settings.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

AcelRx Pharmaceuticals, Inc. competitors and assessment

Company assessment

Broad incumbents

  • Baxter International: Baxter is a global medical products company with significant CRRT/dialysis solutions (e.g., PrisMax, HDx therapy) and a broad injectable pharma portfolio, overlapping directly with Talphera's Niyad (CRRT anticoagulation) and prefilled syringe strategies.
  • Fresenius Medical Care: Fresenius is the largest dialysis products and services provider globally, manufacturing CRRT machines and dialyzers. It is the most natural incumbent peer for Niyad given its dominant share of the U.S. dialysis patient population that would be treated with Niyad.
  • Hikma Pharmaceuticals: Hikma is a multinational specialty pharmaceutical company with a strong hospital injectables business, including prefilled syringes. It is comparable to Talphera in targeting the same perioperative and acute care hospital channel with injectable presentations.
  • Becton, Dickinson and Company (BD): BD is a global leader in prefilled syringes, injection systems, and drug delivery devices, competing with Talphera's Fedsyra and PFS-02 prefilled syringe products in the perioperative and acute care hospital channel.

Direct peers

  • B. Braun Melsungen: B. Braun is a leading manufacturer of prefilled syringes (e.g., ephedrine, phenylephrine ready-to-use injectables) and renal care products, directly comparable to Talphera's Fedsyra/PFS-02 portfolio and the renal care positioning of Niyad.
  • ICU Medical: ICU Medical specializes in IV infusion therapy, critical care, and dialysis connection/disposables, making it a direct peer in the hospital-based infusion and renal care channels that Talphera's products are designed to serve.

Emerging players

  • Outset Medical: Outset Medical produces the Tablo hemodialysis system used in hospitals and at home. As a CRRT/IHD-adjacent company, it shares the renal replacement therapy customer base that Niyad would address.
  • Amphastar Pharmaceuticals: Amphastar is a specialty injectable pharmaceutical company that develops and markets injectable generic and proprietary products, including hospital-based injectables. It is comparable to Talphera's injectable pharmaceutical pipeline and the prefilled syringe strategy.
  • ANI Pharmaceuticals: ANI Pharmaceuticals is a specialty generics and branded pharmaceutical company with a portfolio in critical care and hospital injectables, with a comparable small-cap specialty pharma profile to Talphera.
  • Eagle Pharmaceuticals: Eagle Pharmaceuticals is a specialty pharma focused on hospital-based injectables and ready-to-use formulations, with overlapping strategy around ready-to-use syringe presentations in critical care settings similar to Fedsyra and PFS-02.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

AcelRx Pharmaceuticals, Inc. social profiles

Digital presence

AcelRx Pharmaceuticals, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AcelRx Pharmaceuticals, Inc. leadership team

Management profile

Number of profiles

Profiles11 records

AcelRx Pharmaceuticals, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AcelRx Pharmaceuticals, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AcelRx Pharmaceuticals, Inc.

What does AcelRx Pharmaceuticals, Inc. do?

Talphera (formerly AcelRx Pharmaceuticals) develops and commercializes innovative therapies and drug-device products for use in medically supervised care settings. Its lead product candidate Niyad® (nafamostat mesylate) is a regional anticoagulant for extracorporeal circuits during continuous renal replacement therapy (CRRT), regulated as a device by the FDA. The company also develops prefilled syringe candidates Fedsyra™ (ephedrine) and PFS-02 (phenylephrine) for perioperative hypotension, and LTX-608™, a nafamostat formulation for inflammatory and antiviral indications.

Is AcelRx Pharmaceuticals, Inc. a public or private company?

AcelRx Pharmaceuticals, Inc. is a private company. It is classified as public and is currently operating.

When was AcelRx Pharmaceuticals, Inc. founded?

AcelRx Pharmaceuticals, Inc. was founded in -1.

Where is AcelRx Pharmaceuticals, Inc. based?

AcelRx Pharmaceuticals, Inc. is headquartered in San Mateo, United States, in the North America region.

How does AcelRx Pharmaceuticals, Inc. make money?

Three revenue lines are on record. DSUVIA Royalty Revenue is the primary driver. The others are niyad (future commercial revenue) and prefilled Syringes (future commercial revenue).

Who are AcelRx Pharmaceuticals, Inc.'s main competitors?

Broad incumbents on record are Baxter International, Fresenius Medical Care, Hikma Pharmaceuticals and Becton, Dickinson and Company (BD). Direct peers are B. Braun Melsungen and ICU Medical. Emerging players are Outset Medical, Amphastar Pharmaceuticals, ANI Pharmaceuticals and Eagle Pharmaceuticals.

Does AcelRx Pharmaceuticals, Inc. have an API?

No public API is recorded for AcelRx Pharmaceuticals, Inc..

What industry is AcelRx Pharmaceuticals, Inc. in?

AcelRx Pharmaceuticals, Inc.'s product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAM, Nephrology & Urology Pharmaceuticals, with a secondary code of HLAHAKAK, Renal Care Ancillaries (Anemia Management Devices, Phosphate Binder Support, Nutrition Monitoring). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comU.S. Non Opioid Pain Treatment Market Is Going to Boom | Teva Pharmaceuticals • Amgen • AcelRx PharmaceuticalsCoherent Market Insights has released a market research report forecasting the growth of the U.S. non-opioid pain treatment industry through 2033, highlighting key trends and competitive dynamics. The analysis identifies major pharmaceutical players including AbbVie, Johnson & Johnson, Pfizer, GSK, Teva Pharmaceuticals, Amgen, and AcelRx Pharmaceuticals as central to this evolving sector.PR NewswireAcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023AcelRx Pharmaceuticals announced it will release third quarter 2023 financial results after market close on November 8, 2023, followed by a live webcast and conference call to discuss the results and provide a business update.PR NewswireAcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment ConferenceAcelRx Pharmaceuticals announced that CEO Vince Angotti will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York on September 12, 2023, and will be available for one-on-one meetings with investors throughout the event. The company stated the recorded presentation will be available on its website for 90 days following the conference. This is a routine investor relations announcement with no new business developments, financial results, or strategic updates disclosed.PR NewswireAcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAcelRx Pharmaceuticals reported a Q2 2023 net loss of $4.4 million while completing a $10 million private placement capital raise (with potential additional $16.3 million), fully repaying its senior debt with Oxford, and awaiting FDA response on an Emergency Use Authorization submission for Niyad made in April. The company also completed the divestment of its DSUVIA drug to Alora Pharmaceuticals in April, retaining a 15% royalty on commercial sales and a 75% royalty on Department of Defense sales, plus up to $116.5 million in sales-based milestones. AcelRx expects to initiate a registrational study for Niyad in Q4 2023 with a data readout anticipated for mid-2024.PR NewswireAcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq RulesAcelRx Pharmaceuticals closed a private placement raising $10 million in gross proceeds, with an additional potential $16.3 million available upon the exercise of warrants tied to specific performance milestones. The company intends to use these funds for working capital and to advance its lead product candidate, Niyad, toward a planned PMA submission next year. H.C. Wainwright & Co. served as the exclusive placement agent for this transaction.TalpheraAcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesAcelRx Pharmaceuticals, Inc. announced a definitive agreement for the purchase and sale of 5,340,591 shares of common stock and pre-funded warrants, aiming to raise approximately $10 million. The private placement is priced at $1.36 per share and is expected to close on or about July 20, 2023. Furthermore, if certain milestones are achieved, AcelRx may gain an additional $16.3 million from the exercise of the warrants.PR NewswireAcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023AcelRx Pharmaceuticals announced it will release its full year and fourth quarter 2022 financial results after market close on March 30, 2023, followed by a live webcast and conference call at 4:30 p.m. Eastern Daylight Time. The call will discuss financial results and provide a business update, with dial-in details and webcast access information provided for investors. The press release also includes background on the company's product pipeline, including plans to submit an Emergency Use Authorization for Niyad and an NDA for PFS-01 during Q2 2023.BioSpaceAcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora PharmaceuticalsAcelRx Pharmaceuticals divested its FDA-approved drug DSUVIA to Alora Pharmaceuticals, with closing expected by month-end. The deal includes 15% royalties on commercial sales, 75% on DoD sales, and up to $116.5 million in milestones. AcelRx will focus on its lead nafamostat program Niyad, with an EUA submission expected in Q2 2023.PR NewswireAcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora PharmaceuticalsAcelRx Pharmaceuticals announced the divestment of its FDA-approved drug DSUVIA to Alora Pharmaceuticals, with closing expected by the end of March. The deal includes 15% royalties on commercial sales, 75% on DoD sales, and up to $116.5 million in milestones. AcelRx will focus on its lead nafamostat program Niyad, with an EUA submission expected in Q2 2023.